Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating elexacaftor (VX-661) in combination with ivacaftor in cystic fibrosis patients aged 12+ who are heterozygous for the F508del-CFTR mutat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Elexacaftor (VX-661) (elexacaftor)
• Ivacaftor (Kalydeco) (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-06-12